Polydex Pharmaceuticals (POLXF) & Its Peers Head-To-Head Survey

Polydex Pharmaceuticals (OTCMKTS: POLXF) is one of 17 publicly-traded companies in the “Industrial inorganic chemicals” industry, but how does it contrast to its competitors? We will compare Polydex Pharmaceuticals to similar businesses based on the strength of its risk, dividends, earnings, institutional ownership, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares Polydex Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Polydex Pharmaceuticals $4.86 million $210,000.00 -23.79
Polydex Pharmaceuticals Competitors $3.74 billion $366.26 million 7.62

Polydex Pharmaceuticals’ competitors have higher revenue and earnings than Polydex Pharmaceuticals. Polydex Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Polydex Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Polydex Pharmaceuticals’ competitors have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Polydex Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polydex Pharmaceuticals 0 0 0 0 N/A
Polydex Pharmaceuticals Competitors 133 424 626 12 2.43

As a group, “Industrial inorganic chemicals” companies have a potential upside of 6.99%. Given Polydex Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Polydex Pharmaceuticals has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

47.5% of shares of all “Industrial inorganic chemicals” companies are owned by institutional investors. 12.9% of Polydex Pharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of shares of all “Industrial inorganic chemicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Polydex Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Polydex Pharmaceuticals -2.92% -2.21% -1.85%
Polydex Pharmaceuticals Competitors 2.89% 9.83% 2.88%

Summary

Polydex Pharmaceuticals competitors beat Polydex Pharmaceuticals on 9 of the 10 factors compared.

About Polydex Pharmaceuticals

Polydex Pharmaceuticals Ltd. engages in the manufacture and sale of bulk quantities of dextran and derivative products to large pharmaceutical companies. It develops and market biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada.

Receive News & Ratings for Polydex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polydex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.